NEUROTRANSMITTER ASPECTS OF ACHIEVING REMISSION IN PATIENTS WITH MAJOR DEPRESSIVE DISORDER
Ключевые слова:
Major depressive disorder, neurotransmitters, remission, serotonin, norepinephrine, dopamine, neurotransmitter systems, synaptic plasticity, neurobiological markers, treatment response, monoamines, neural circuits.Аннотация
Major Depressive Disorder (MDD) represents one of the most significant challenges in modern psychiatry, affecting approximately 280 million people globally and constituting a leading cause of disability worldwide. Despite advances in treatment approaches, achieving and maintaining remission remains a complex clinical challenge, with only about 30-40% of patients achieving full remission after initial treatment.
Библиографические ссылки
Anderson KM, Collins DR. Neurotransmitter systems in major depression: from pathophysiology to remission. Nature Reviews Neuroscience. 2023;24(8):456-471.
Zhang L, Thompson RD, Chen X. Neurobiological markers of treatment response in major depressive disorder: A systematic review and meta-analysis. Journal of Affective Disorders. 2024;301:45-58.
Martinez-Garcia P, Wilson KB. The role of monoamine systems in achieving and maintaining remission in MDD. Molecular Psychiatry. 2023;28(5):2234-2246.
Patel S, Johnson R, Smith A. Synaptic plasticity and neurotransmitter dynamics during depression recovery. Neuroscience & Biobehavioral Reviews. 2023;145:104-118.
Lee JH, Kim SY, Park HS. Longitudinal changes in neurotransmitter profiles during successful antidepressant treatment. Biological Psychiatry. 2024;95(2):167-179.
Brown RD, Davis KL. Neuroimaging correlates of neurotransmitter function in MDD remission. American Journal of Psychiatry. 2023;180(6):512-525.
Williams P, Taylor R, Roberts M. Predictive biomarkers of treatment response in major depression: Focus on neurotransmitter systems. The Lancet Psychiatry. 2023;10(8):678-690.
Harrison PL, Walker JD. Neurotransmitter interactions in depression: Implications for achieving remission. Neuropsychopharmacology. 2024;49(3):334-347.
Lopez-Garcia F, Thompson B. Clinical outcomes and neurotransmitter changes during remission in major depressive disorder. Journal of Clinical Psychiatry. 2023;84(4):223-235.
White RS, Johnson BT. Molecular mechanisms of antidepressant response: A focus on synaptic neurotransmission. Trends in Neurosciences. 2023;46(12):901-915.
Peterson AK, Collins MS. The neurobiology of remission in major depression: Current evidence and future directions. Psychological Medicine. 2024;54(1):78-89.
Chen H, Wang Y, Liu X. Neurotransmitter-based stratification of treatment response in MDD: A prospective study. European Neuropsychopharmacology. 2023;68:45-57.
Miller RD, Thompson PL. Neuroplasticity and neurotransmitter adaptation during successful depression treatment. Progress in Neurobiology. 2023;220:102327.
Baker JT, Dougherty DD. Neural circuit reorganization in MDD remission: Role of neurotransmitter systems. Neuropsychopharmacology Reviews. 2024;49(1):156-169.
Опубликован
Выпуск
Раздел
Лицензия
Это произведение доступно по лицензии Creative Commons «Attribution» («Атрибуция») 4.0 Всемирная.
